Metoprolol succinate pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers
Extended-Release Metoprolol Succinate Pharmacokinetics
Extended-release (ER) metoprolol succinate is formulated to provide a steady release of metoprolol over approximately 20 to 24 hours, resulting in more consistent plasma concentrations compared to immediate-release (IR) formulations. This controlled release minimizes the peaks and troughs in drug levels, leading to a stable β1-blockade throughout the dosing interval and allowing for convenient once-daily dosing 1389. The ER formulation is designed to be independent of food intake and gastrointestinal pH, further supporting its consistent pharmacokinetic profile 38.
Absorption, Distribution, and Elimination
After oral administration, metoprolol succinate is absorbed and reaches its maximal plasma concentration (Cmax) within a few hours. In animal studies, the half-life of metoprolol succinate was found to be approximately 3.9 hours, with a high recovery rate, indicating efficient absorption and measurement in plasma . In humans, the ER formulation maintains higher plasma concentrations at the end of the dosing interval compared to conventional tablets, despite having a lower peak concentration 138. This results in a more even pharmacodynamic effect, particularly in maintaining heart rate control over 24 hours 139.
Influence of Genetic and Drug Interactions
Metoprolol is primarily metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme. Genetic differences in CYP2D6 activity significantly affect metoprolol pharmacokinetics. Poor metabolizers exhibit much higher plasma concentrations, longer half-life, and reduced clearance compared to extensive or ultrarapid metabolizers. The differences in peak concentration, area under the curve (AUC), and clearance can be several-fold between these groups, highlighting the importance of genetic variability in dosing and response .
Certain substances can also alter metoprolol succinate pharmacokinetics. For example, co-administration with naringenin or hesperetin (flavonoids found in citrus fruits) in animal studies increased metoprolol’s Cmax, AUC, and half-life, while decreasing clearance and volume of distribution. These effects are likely due to inhibition of CYP enzymes and P-glycoprotein, which are involved in metoprolol metabolism and transport 47.
Bioequivalence and Food Effects
Studies in healthy subjects have shown that different ER metoprolol succinate formulations are bioequivalent, with similar AUC and Cmax values under both fasting and fed conditions. This means that the pharmacokinetic profile is consistent regardless of food intake, and both test and reference products are well tolerated .
Combination Therapy and Safety
When metoprolol succinate is combined with other antihypertensive agents, such as telmisartan, there is no significant pharmacokinetic interaction observed in animal studies. The combination is effective in lowering blood pressure and does not increase toxicity, supporting its use in combination therapy for hypertension 58.
Conclusion
Metoprolol succinate extended-release provides stable and predictable pharmacokinetics, with consistent plasma concentrations and β1-blockade over 24 hours. Its metabolism is strongly influenced by CYP2D6 genetic variability and can be affected by certain dietary components or drugs that inhibit CYP enzymes. The ER formulation is bioequivalent across different products and is not significantly affected by food, making it a reliable option for once-daily dosing in hypertension and heart failure management 1368+2 MORE.
Sources and full results
Most relevant research papers on this topic